

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

HT-1197

RRID:CVCL_1291

Type: Cell Line

Proper Citation

RRID:CVCL_1291

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1291

Proper Citation: RRID:CVCL_1291

Description: Cell line HT-1197 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Recurrent bladder carcinoma

Defining Citation: [PMID:191628](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:6244232](#), [PMID:7787250](#), [PMID:8873383](#), [PMID:11416159](#), [PMID:11921286](#), [PMID:12068308](#), [PMID:15846775](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25984343](#), [PMID:25997541](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HT-1197

Synonyms: HT 1197, HT1197, HT 1197.T

Cross References: BTO:BTO_0004124, CLO:CLO_0004267, CLO:CLO_0004278, EFO:EFO_0002202, CLDB:cl1734, CLDB:cl7161, ArrayExpress:E-MTAB-38,

ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1473, ATCC:CRL-7926, BCRC:60059, BioGRID_ORCS_Cell_line:415, BioSample:SAMN03471362, BioSample:SAMN10988033, cancercellines:CVCL_1291, Cell_Model_Passport:SIDM00676, ChEMBL-Cells:ChEMBL3308506, ChEMBL-Targets:ChEMBL614836, CLS:305800, Cosmic:715772, Cosmic:760473, Cosmic:845563, Cosmic:907065, Cosmic:925822, Cosmic:928814, Cosmic:1285117, Cosmic:1285988, Cosmic:1927306, Cosmic:2037946, Cosmic:2050443, Cosmic:2057448, Cosmic:2444236, Cosmic:2685944, Cosmic-CLP:907065, DepMap:ACH-000547, ECACC:87032403, EGA:EGAS00001000978, ENCODE:ENCBS699THW, ENCODE:ENCBS772EGW, GDSC:907065, GEO:GSM136229, GEO:GSM142304, GEO:GSM827290, GEO:GSM887138, GEO:GSM888209, GEO:GSM1374559, GEO:GSM1669910, IARC_TP53:3719, IARC_TP53:21130, ICLC:HTL04006, IGRhCellID:HT1197, KCLB:21473, LiGeA:CCL_192, LINCS_LDP:LCL-1713, PharmacDB:HT1197_627_2019, PRIDE:PXD030304, Progenetix:CVCL_1291, PubChem_Cell_line:CVCL_1291, SKY/M-FISH/CGH:1463, Wikidata:Q54896502

ID: CVCL_1291

Record Creation Time: 20220427T220617+0000

Record Last Update: 20260905T180809+0000

Ratings and Alerts

No rating or validation information has been found for HT-1197.

Warning: Discontinued: ATCC; CRL-7926

Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cheng LH, et al. (2026) Chemotherapy resistance of urinary bladder cancer mediated by a Notch and Wnt co-regulatory module of stemness. Stem cells (Dayton, Ohio), 44(4).

Bevilacqua R, et al. (2026) Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies. NPJ precision oncology, 10(1).

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. *Molecular oncology*, 20(3), 823.

Stuckey JI, et al. (2026) Covalent PPAR γ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR γ /RXR γ -activated urothelial carcinoma. *Cell chemical biology*, 33(6), 837.

Osborne N, et al. (2025) Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab. *Oncoimmunology*, 14(1), 2494995.

Hernández-Prat A, et al. (2024) Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. *Molecular oncology*.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Jinesh GG, et al. (2024) C19MC drives nucleolar invasion of mitochondria and meiotic nuclear division in human cancers. *iScience*, 27(11), 111132.

Jung J, et al. (2021) p53 mitigates the effects of oncogenic HRAS in urothelial cells via the repression of MCOLN1. *iScience*, 24(7), 102701.